Stock A326030 SK BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

SK Biopharmaceuticals Co., Ltd. Stock

Equities

A326030

KR7326030004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
86,600 KRW -1.93% Intraday chart for SK Biopharmaceuticals Co., Ltd. +3.71% -13.75%
Jan. 30 SK Biopharmaceuticals Swings to Profit in Q4 MT
2023 SK Group Advances Net Zero Transition via Key Renewable Energy Deal MT

Financials

Sales 2024 * 485B 356M Sales 2025 * 651B 478M Capitalization 6,782B 4.98B
Net income 2024 * 31B 22.75M Net income 2025 * 118B 86.61M EV / Sales 2024 * 13.7 x
Net cash position 2024 * 145B 106M Net cash position 2025 * 261B 192M EV / Sales 2025 * 10 x
P/E ratio 2024 *
212 x
P/E ratio 2025 *
51.9 x
Employees 252
Yield 2024 *
-
Yield 2025 *
-
Free-Float 35.75%
More Fundamentals * Assessed data

Chart SK Biopharmaceuticals Co., Ltd.

Dynamic Chart

Latest news about SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals Swings to Profit in Q4 MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal MT
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CI
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference CI
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd.. CI
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2% MT
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division MT
SK Biopharmaceuticals Continues to Report Losses in Q2 MT
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation CI
SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029 MT
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million. CI
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
SK Biopharmaceuticals Narrows Loss in Q1 MT
SK Biopharmaceuticals Swings to Loss in Q4 MT
SK Biopharmaceuticals' Anti-Epilepsy Treatment Cenobamate Approve for Sale in France MT
More news

Analyst Recommendations on SK Biopharmaceuticals Co., Ltd.

South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2% MT
More recommendations

Press releases SK Biopharmaceuticals Co., Ltd.

SK Life Science - XCOPRI CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube AQ
SK Life Science Celebrates Purple Day Highlighting Partnerships and Tools Designed to Empower People Living with Epilepsy in Their Journey to Achieve Zero Seizures AQ
Hikma and SK Biopharmaceuticals enter a strategic partnership for the Middle East and North Africa AQ
SK to Showcase 40 Carbon Reduction Technologies at CES 2023 AQ
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France AQ
More press releases

Quotes and Performance

1 day-1.93%
1 week+3.71%
Current month-1.14%
1 month-1.81%
3 months-6.28%
6 months+12.03%
Current year-13.75%
More quotes

Highs and lows

1 week
83 800.00
Extreme 83800
90 500.00
1 month
80 700.00
Extreme 80700
90 500.00
Current year
80 700.00
Extreme 80700
104 800.00
1 year
69 200.00
Extreme 69200
104 800.00
3 years
50 900.00
Extreme 50900
137 500.00
5 years
50 900.00
Extreme 50900
269 500.00
10 years
50 900.00
Extreme 50900
269 500.00
More quotes

Managers and Directors - SK Biopharmaceuticals Co., Ltd.

Managers TitleAgeSince
Dong-Hoon Lee CEO
 Chief Executive Officer 56 22-12-31
Choi Jonggil PRN
 Corporate Officer/Principal - 22-12-31
Jeong-Woo Jo PRN
 Corporate Officer/Principal - 17-03-15
Members of the board TitleAgeSince
Geun-Joo Hwang BRD
 Director/Board Member 60 17-03-15
Jeong-Woo Jo PRN
 Corporate Officer/Principal - 17-03-15
Young-Ju Bang BRD
 Director/Board Member - 19-08-26
More insiders

ETFs positioned on SK Biopharmaceuticals Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
1.83% 2 M€ -14.14%
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS Emerging Market Equity MSCI-EM (Unhedged) ETF - JPY
0.08% 15 M€ +12.19%
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR
0.03% 2,808 M€ +8.23% -
More ETFs positioned on SK Biopharmaceuticals Co., Ltd.

Quotes

Date Price Change Volume
24-05-03 86,600 -1.93% 62,483
24-05-02 88,300 +0.80% 72,720
24-04-30 87,600 +1.98% 174,895
24-04-29 85,900 +2.87% 91,765
24-04-26 83,500 +0.24% 37,526

End-of-day quote Korea S.E., May 02, 2024

More quotes

Company Profile

SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business.
Sector
Pharmaceuticals
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for SK Biopharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
86,600 KRW
Average target price
106,133 KRW
Spread / Average Target
+22.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-13.75% 5.01B
MERCK KGAA Stock Merck KGaA
+5.48% 71.19B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.55% 9.3B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.38% 4.47B
YUHAN CORPORATION Stock Yuhan Corporation
+4.51% 3.96B
INDIVIOR PLC Stock Indivior PLC
+21.10% 2.44B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.05% 2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.72% 2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.13% 2.02B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+6.53% 1.69B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A326030 Stock